ERBB2 and breast carcinoma: Compounds with the pharmacophore, such as NSC624205 and RBF3, displayed stronger effects toward EGFR+ (MDA-MB-468) and HER2+ (BT-474) breast cancers compared with the pancreatic cancer cell line (BxPC-3).